Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People
Sponsor: Novo Nordisk A/S
Summary
This study is testing a new medicine, in healthy adults to assess its safety and understand how it behaves in the body. The purpose of this study is to evaluate the safety, tolerability, and how the body responds to a single dose of NNC0642-1895 in healthy adults. Participant will either get study medicine (NNC0642-1895) or placebo (a treatment that has no active medicine in it). Which treatment a participant receives is decided by chance. NNC0642-1895 is a new medicine that is being tested in humans for the first time and is not currently available for doctors to prescribe. The study will last for about 94 days (approximately 14 weeks).
Official title: A First in Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Intravenous Administrations of NNC0642-1895 in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
148
Start Date
2026-09-17
Completion Date
2027-09-12
Last Updated
2026-09-21
Healthy Volunteers
Yes
Conditions
Interventions
NNC0642-1895
NNC0642-1895 will be administered intravenously.
Placebo
Placebo will be administered intravenously.
Locations (1)
ICON-Salt Lake City
Salt Lake City, Utah, United States